<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353596</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2020-001206-35</org_study_id>
    <nct_id>NCT04353596</nct_id>
  </id_info>
  <brief_title>Stopping ACE-inhibitors in COVID-19</brief_title>
  <acronym>ACEI-COVID</acronym>
  <official_title>Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that&#xD;
      stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor&#xD;
      blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The COVID-19 pandemic currently poses unprecedented challenges to the health systems of all&#xD;
      countries. Experimental studies show that the SARS-CoV2 virus enters human cells via the&#xD;
      angiotensin converting enzyme II receptor 2 (ACE2). ACE inhibitors (ACEI) and angiotensin&#xD;
      receptor blockers (ARB) can lead to an increase in the expression of ACE2. Therefore, there&#xD;
      is concern that in patients treated with ACEI or ARB, the absorption of the virus is&#xD;
      facilitated, thereby accelerating its spread in the body.&#xD;
&#xD;
      ACEI-COVID tests the hypothesis that stopping chronic ACEI / ARB therapy in&#xD;
      SARS-CoV2-infected patients improves outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Actual">February 24, 2021</completion_date>
  <primary_completion_date type="Actual">February 16, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label, randomized design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>unmasked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death</measure>
    <time_frame>30 days</time_frame>
    <description>The minimal value of the SOFA Score will be 0 and the maximal value 24 points. All-cause death is classified as the maximum score (24 points). In case of a subclinical disease progress without need for hospitalization, the SOFA score will be 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death</measure>
    <time_frame>30 days</time_frame>
    <description>will be hierarchically tested after enrollment of 798 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean and area under the curve of Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>30 days</time_frame>
    <description>minimum score is 0, maximum score is 24; higher score indicates poor outcome (death-adjusted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of non-invasive ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>high-flow, continuous positive airway pressure therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of renal replacement therapies</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of viral burden</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with systolic/diastolic blood pressure &gt; 180/120 mmHg</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation due to cardiac decompensation</measure>
    <time_frame>30 days</time_frame>
    <description>with causal relationship to stopping of ACEI/ARB therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of clonal hematopoiesis of indeterminate potential (CHIP)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Stopping/replacing ACEI/ARB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic treatment with ACEI or ARB will be stopped or replaced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention, which means further treatment with ACEI or ARB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor, angiotensin receptor blocker</intervention_name>
    <description>In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.</description>
    <arm_group_label>Stopping/replacing ACEI/ARB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male patients competent to make a decision&#xD;
&#xD;
          -  Proven and symptomatic SARS-CoV2 infection ≤ 5 days&#xD;
&#xD;
          -  Patient age ≥ 18 years&#xD;
&#xD;
          -  Provided written informed consent&#xD;
&#xD;
          -  Chronic (≥ 1 month) ACEI/ARB therapy for treatment of arterial hypertension, diabetes&#xD;
             mellitus, heart failure or coronary artery disease&#xD;
&#xD;
          -  Stable hemodynamic conditions allowing to stop or continue treatment with ACEI/ARB&#xD;
             (systolic blood pressure ≤180mmHg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women capable of bearing children as well as pregnant and breastfeeding women&#xD;
&#xD;
          -  Participant in another interventional trail&#xD;
&#xD;
          -  At screening visit, no oral medication intake possible&#xD;
&#xD;
          -  Advanced heart failure NYHA Stage III-IV&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;30% or NTproBNP ≥600pg/mL in case of clinical&#xD;
             signs of heart failure&#xD;
&#xD;
          -  Acute coronary syndrome ≤ 3 months&#xD;
&#xD;
          -  Severe arterial hypertension (concomitant use of more than 4 different&#xD;
             antihypertensive drug classes)&#xD;
&#xD;
          -  Acute respiratory distress syndrome with need for mechanical ventilation&#xD;
&#xD;
          -  Patients who at not capable of home blood pressure monitoring&#xD;
&#xD;
          -  Patients who cannot be switched to an alternative medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Innsbruck, University Hospital of Internal Medicine III</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Hall</name>
      <address>
        <city>Hall In Tirol</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, Intensive Care and Emergency Medicine Department</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, University Hospital of Internal Medicine II</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, University Hospital of Internal Medicine IV</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, University Hospital of Internal Medicine I</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, University Hospital of Internal Medicine V</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lienz</name>
      <address>
        <city>Lienz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus St. Johann</name>
      <address>
        <city>Sankt Johann In Tirol</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Schwaz</name>
      <address>
        <city>Schwaz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Vinzenz Zams</name>
      <address>
        <city>Zams</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum, Medizinische Klinik I</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Stadtklinik Bad Tölz</name>
      <address>
        <city>Bad Tölz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dachau</name>
      <address>
        <city>Dachau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen</name>
      <address>
        <city>Memmingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum, Medizinische Klinik III</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum, Medizinische Klinik II</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum, Medizinische Klinik IV</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>München Klinik Bogenhausen und Schwabing</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Mühldorf</name>
      <address>
        <city>Mühldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Weiden</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACE-inhibitors</keyword>
  <keyword>RAS system</keyword>
  <keyword>angiotensin receptor blockers</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

